Abstract:Background: Non-responsiveness is a major barrier in current cancer immune checkpoint blockade therapies, and the mechanism has not been elucidated yet. Therefore, it is necessary to discover the mechanism and biomarkers of tumor immunotherapeutic resistance.Methods: Bioinformatics analysis was performed based on CD8(+) T cell infiltration in multiple tumor databases to screen out genes related to anti-tumor immunity. Associations between Regulator of G-protein signaling 1 (RGS1) and IFN gamma-STAT1 signaling, and MHCI antigen presentation pathway were examined by RT-qPCR, western blotting, and flow cytometry. The modulatory mechanisms of RGS1 were investigated via CHIP-qPCR and dual-luciferase assay. The clinical and therapeutic implications of RGS1 were comprehensively investigated using tumor cell lines, mouse models, and clinical samples receiving immunotherapy.Results: RGS1 was identified as the highest gene positively correlated with immunogenicity among RGS family. Inhibition of RGS1 in neoplastic cells dampened anti-tumor immune response and elicited resistance to immunotherapy in both renal and lung murine subcutaneous tumors. Mechanistically, RGS1 enhanced the binding of activating transcription factor 3 (ATF3) to the promoter of interferon gamma receptor 1 (IFNGR1), activated STAT1 and the subsequent expression of IFN gamma-inducible genes, especially CXCL9 and MHC class I (MHCI), thereby influenced CD8(+) T cell infiltration and antigen presentation and processing. Clinically, lower expression level of RGS1 was associated with resistance of PD1 inhibition therapy and shortened progression-free survival among 21 NSCLC patients receiving immunotherapy.Conclusions: Together, these findings uncover a novel mechanism that elicits immunotherapy resistance and highlight the function of tumor-intrinsic RGS1, which brings new insights for future strategies to sensitize anti-PD1 immunotherapy.

Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy

Dual role of interferons in tumor immunology

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

Tumor Immune Checkpoints and Their Associated Inhibitors

Roles of IFN-γ in tumor progression and regression: a review

Double-edged Roles of IFNγ in Tumor Elimination and Immune Escape

Interferon Gamma in Cancer Immunotherapy

Low-dose IFN-γ induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer

Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion

Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non–Small Cell Lung Cancer

Cancer Cell Resistance to IFNγ Can Occur Via Enhanced Double-Strand Break Repair Pathway Activity.

Type I interferon-mediated tumor immunity and its role in immunotherapy

Tumor-intrinsic RGS1 Potentiates Checkpoint Blockade Response Via ATF3-IFNGR1 Axis

Overcoming Immunotherapy Resistance in Melanoma Defective of IFN-γ Signaling

The Diverse Pancreatic Tumor Cell-Intrinsic Response to IFNγ is Determined by Epigenetic Heterogeneity.

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

IFN-γ Mediates CD4+ T-cell Loss and Impairs Secondary Antitumor Responses after Successful Initial Immunotherapy

Selective Suppression of Melanoma Lacking IFN-γ Pathway by JAK Inhibition Depends on T Cells and Host TNF Signaling

Type I Interferon Suppresses Tumor Growth Through Activating the STAT3-granzyme B Pathway in Tumor-Infiltrating Cytotoxic T Lymphocytes

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

IFNγ signaling integrity in colorectal cancer immunity and immunotherapy